raloxifene sold brand name evista among others medication used prevent treat osteoporosis postmenopausal women osteoporosis less preferred also used reduce risk breast cancer high taken common side effects include hot flashes leg cramps swelling joint severe side effects may include blood clots use pregnancy may harm medication may worsen menstrual raloxifene selective estrogen receptor modulator serm therefore mixed estrogen receptor estrogenic effects bone antiestrogenic effects breasts raloxifene approved medical use united states available generic commonly prescribed medication united states million raloxifene used treatment prevention osteoporosis postmenopausal used dosage mgday prevention treatment case either osteoporosis prevention treatment supplemental calcium vitamin added diet daily intake raloxifene used reduce risk breast cancer postmenopausal women used dosage mgday multiple outcomes raloxifene clinical trial raloxifene decreased risk types breast cancer invasive breast cancer invasive estrogen receptorpositive breast cancer conversely reduce risk estrogen receptornegative breast obvious differences effectiveness raloxifene trial prevention breast cancer dosage relative study tamoxifen raloxifene star trial mgday raloxifene effective mgday tamoxifen preventing noninvasive breast women undetectable levels estradiol pgml naturally low risk breast cancer contrast women detectable levels estradiol experience significant benefit raloxifene terms reduction breast cancer raloxifene contraindicated lactating women women may become also may concern women active past history venous thromboembolic events including deep vein thrombosis pulmonary embolism retinal vein common side effects raloxifene include hot flashes vs vaginal dryness leg cramps generally mild vs raloxifene cause breast tenderness endometrial hyperplasia menstrual bleeding endometrial appear affect cognition raloxifene teratogen ie cause developmental abnormalities birth defects raloxifene may infrequently cause serious blood clots form legs lungs reactions experienced include leg swellingpain trouble breathing chest pain vision changes black box warnings added label raloxifene warning increased risk death due stroke postmenopausal women documented coronary heart disease increased risk major coronary events well increased risk deep vein thrombosis pulmonary risk venous thromboembolism raloxifene increased severalfold postmenopausal women rrtooltip relative risk raloxifene lower risk thromboembolism trial raloxifene caused decrease risk cardiovascular events women increased risk coronary artery disease although decrease cardiovascular events group report september health human services agency healthcare research quality suggests tamoxifen raloxifene used treat breast cancer significantly reduce invasive breast cancer midlife older women also increase risk adverse side recent human case report july suggests raloxifene may fact point also stimulate breast cancer growth leading reduction advanced breast cancer disease upon withdrawal unlike serms tamoxifen raloxifene risk uterine hyperplasia endometrial cancer rrtooltip relative risk raloxifene increase incidence breast pain tenderness postmenopausal raloxifene studied clinical trials across dosage range mgday welltolerated raloxifene selective estrogen receptor modulator serm hence mixed agonist antagonist estrogen receptor er different estrogenic activity tissues bone liver antiestrogenic activity tissues breasts affinity kd erα approximately pm similar relative estradiol raloxifene reported possess affinity erα affinity raloxifene acts partial agonist erα pure antagonist contrast classical ers raloxifene agonist g proteincoupled estrogen receptor gper halfmaximal effective concentration nm membrane estrogen raloxifene antiestrogenic effects mammary glands preclinical accordance raloxifene reduces breast density postmenopausal women known risk factor breast stimulate uterus postmenopausal women results increase risk endometrial thickening vaginal bleeding endometrial hyperplasia endometrial time raloxifene minimal antiestrogenic effect uterus premenopausal may possibly due inadequate tissue exposure uterus raloxifene estrogenrich premenopausal women raloxifene increases levels folliclestimulating hormone fsh conversely postmenopausal women raloxifene found reduce levels gonadotropins luteinizing hormone lh fsh affecting levels raloxifene also decreases prolactin levels postmenopausal men raloxifene found disinhibit axis hpg axis thereby increase total testosterone due simultaneous increase sex hormonebinding globulin shbg levels however free testosterone levels often remain unchanged men therapy raloxifene estrogenic effects liver protein increases shbg levels pre postmenopausal women well medication decreases levels total lowdensity lipoprotein ldl cholesterol creactive protein apolipoprotein b conversely little effect levels triglycerides highdensity lipoprotein raloxifene shown inhibit oxidation ldl cholesterol medication found decrease insulinlike growth factor levels pre postmenopausal women well also found increase insulinlike growth factor binding protein levels pre postmenopausal due activation estrogen receptors liver raloxifene procoagulatory effects decreasing levels fibrinogen influencing levels coagulation reasons raloxifene increases risk raloxifene increases bone mineral density postmenopausal women decreases premenopausal trial risk vertebral fractures decreased bone mineral density increased spine mg mg femoral neck mg found possess estrogenic effects adipose tissue postmenopausal women promoting shift android fat distribution gynoid fat medication found increase levels leptin absorption raloxifene approximately however due extensive firstpass metabolism absolute bioavailability raloxifene raloxifene rapidly absorbed intestines upon oral peak plasma levels raloxifene occur hours oral healthy postmenopausal women treated mgday raloxifene peak circulating raloxifene levels normalized dose body weight ie divided mgkg ngml pgml single dose ngml pgml multiple raloxifene widely distributed throughout extensive distribution raloxifene liver serum lungs volume distribution raloxifene single mg oral dose approximately lkg corresponds l kg raloxifene glucuronide metabolites show high plasma protein binding including albumin acid glycoprotein sex hormonebinding specifically raloxifene bound plasma raloxifene metabolized liver undergoes enterohepatic metabolized exclusively glucuronidation metabolized cytochrome less radiolabeled material plasma comprises unconjugated metabolites raloxifene include several elimination halflife raloxifene single dose hours days whereas halflife steady state dosage mgday hours days average hours extended halflife raloxifene attributed enterohepatic recirculation high plasma protein raloxifene glucuronide conjugates interconverted reversible metabolism enterohepatic recycling prolongs elimination halflife raloxifene oral medication deconjugated active form variety tissues including liver lungs spleen bone uterus raloxifene mainly excreted bile eliminated less dose excreted unchanged urine less dose excreted urine glucuronide raloxifene hydrochloride empirical formula corresponds molecular weight gmol raloxifene hydrochloride offwhite paleyellow solid slightly soluble raloxifene benzothiophene derivative structurally distinct triphenylethylene serms like tamoxifen clomifene benzothiophene serm benzothiophene serm marketed arzoxifene bazedoxifene duavee viviant pipendoxifene structurally related raloxifene technically benzothiophenes instead raloxifene approved united states prevention postmenopausal osteoporosis treatment postmenopausal osteoporosis prevent reduce risk breast cancer certain postmenopausal women received orphan designation raloxifene generic name drug inntooltip international nonproprietary name bantooltip british approved name raloxifène dcftooltip dénomination commune française raloxifene hydrochloride usantooltip united states adopted name banmtooltip british approved name jantooltip japanese accepted also known name raloxifene sold mainly brand name evista lesser extent brand name also sold variety brand names various raloxifene available widely throughout world including united states canada united kingdom ireland elsewhere throughout europe australia new zealand south africa latin america southern eastern southeastern asia elsewhere world israel raloxifene provided form mg oral editorial lancet oncology criticized way research medication breast cancer prevention clinical studies raloxifene metastatic breast cancer women conducted found little effectiveness mgday previously treated tamoxifen though modest effectiveness observed higher contrast tamoxifen raloxifene approved treatment breast raloxifene studied men variety uses treatment schizophrenia prostate cancer studied combination castration bicalutamide nonsteroidal antiandrogen treatment prostate raloxifene studied adjunct treatment schizophrenia postmenopausal metaanalysis concluded safe effective indication although studies larger sample sizes needed may effective women less severe tissueselective estrogenreceptor complex tsec estradiol raloxifene studied postmenopausal raloxifene mgday reported effective treatment pubertal gynecomastia adolescent boys small retrospective chart serms also known effective treatment raloxifene reported augment antidepressant effects selective serotonin reuptake inhibitors june privatepublic consortium supported eu horizon programme research innovation led dompé farmaceutici currently representing partners including fraunhofer institute cineca chelonia applied science swiss institute bioinformatics others requested access clinical trials use raloxifene patients raloxifene already proven effective mers sars preclinical tests indicated effective insilico research conducted consortium shown efficacy countering replication virus cells ip use already protected may name dompé farmaceutici fraunhofer institute ku leuven facilitate largest possible access raloxifene would used mildly symptomatic patients halt spread infection result emerged first virtual silico screening conducted consortium supercomputers molecules safeinman drugs natural products made available dompé farmaceutici partner fraunhofer ime consortium molecules prioritized clinical stage already market molecules certain promising characteristics tested httpsenwikipediaorgwikiraloxifene